Limited access to transcranial Doppler screening and stroke prevention for children with sickle cell disease in Europe: Results of a multinational EuroBloodNet survey.
EuroBloodNet
Europe
children
sickle cell disease
stroke
transcranial Doppler
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
revised:
17
06
2024
received:
05
01
2024
accepted:
25
06
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
Ensuring equitable access to adequate standard of care for patients with rare hematological disease is one of the aims of the European Reference Network (ERN) EuroBloodNet. Stroke is one of the most devastating complications for children with sickle cell disease (SCD). For effective prevention of stroke risk, annual transcranial Doppler (TCD) according to a defined protocol is recommended for patients aged 2-16 years, with red blood cell transfusion therapy for those at risk. There is no information regarding screening for stroke risk and stroke prevention programs in Europe. Seven SCD experts of five healthcare providers (HCPs) of ERN EuroBloodNet developed an online survey to assess the access to TCD screening and stroke prevention programs for children with SCD in Europe. Eighty-one experts in 77 HCPs from 16 European countries responded to 16 online questions. Thirty-two of 77 (51%) HCPs were EuroBloodNet reference centers, and 36% physicians reported not having a dedicated TCD/TCD imaging service for children with SCD. Only 30% of physicians provided estimates that all their patients received annual TCD according to the standard protocol due to lack of trained staff (43%), lack of TCD instruments (11%), refusal of patients due to logistical difficulties (22%), and lack of funds for dedicated staff or equipment (11%). This multinational European survey provides the first comprehensive picture of access to TCD screening and stroke prevention in European countries. Identifying the potential underlying causes of the lack of effective standardized screening, this survey also addresses possible dedicated actions to cover these needs.
Sections du résumé
BACKGROUND
BACKGROUND
Ensuring equitable access to adequate standard of care for patients with rare hematological disease is one of the aims of the European Reference Network (ERN) EuroBloodNet. Stroke is one of the most devastating complications for children with sickle cell disease (SCD). For effective prevention of stroke risk, annual transcranial Doppler (TCD) according to a defined protocol is recommended for patients aged 2-16 years, with red blood cell transfusion therapy for those at risk. There is no information regarding screening for stroke risk and stroke prevention programs in Europe.
METHODS
METHODS
Seven SCD experts of five healthcare providers (HCPs) of ERN EuroBloodNet developed an online survey to assess the access to TCD screening and stroke prevention programs for children with SCD in Europe.
RESULTS
RESULTS
Eighty-one experts in 77 HCPs from 16 European countries responded to 16 online questions. Thirty-two of 77 (51%) HCPs were EuroBloodNet reference centers, and 36% physicians reported not having a dedicated TCD/TCD imaging service for children with SCD. Only 30% of physicians provided estimates that all their patients received annual TCD according to the standard protocol due to lack of trained staff (43%), lack of TCD instruments (11%), refusal of patients due to logistical difficulties (22%), and lack of funds for dedicated staff or equipment (11%).
CONCLUSIONS
CONCLUSIONS
This multinational European survey provides the first comprehensive picture of access to TCD screening and stroke prevention in European countries. Identifying the potential underlying causes of the lack of effective standardized screening, this survey also addresses possible dedicated actions to cover these needs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31190Subventions
Organisme : European Reference Network on Rare Hematological Diseases
ID : 10108571
Organisme : ERN-EuroBloodNet
Organisme : European Union within the framework of the Fourth EU Health Programme
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Brousse V, Kossorotoff M, de Montalembert M. How I manage cerebral vasculopathy in children with sickle cell disease. Br J Haematol. 2015;170:615‐625.
Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med. 1992;326(9):605‐610.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5‐11.
DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554‐1588.
Allali S, Taylor M, Brice J, de Montalembert M. Chronic organ injuries in children with sickle cell disease. Haematologica. 2021;106(6):1535‐1544.
Colombatti R, Perrotta S, Samperi P, et al. Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis. 2013;8:169.
de Montalembert M, Ferster A, Colombatti R, Rees DC, Gulbis B, European Network for Rare and Congenital Anaemias. ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. Am J Hematol. 2011;86(1):72‐75.
Cario HGR, Jarisch A, Kulozik AE, Kunz JB, Lobitz S. AWMF‐Leitlinie 025/016 Sichelzellkrankheit. AWFM; 2014. Accessed August 1, 2023. https://www.awmf.org/uploads/tx_szleitlinien/025‐016l_S2k_Sichelzellkrankheit_2014‐12_verlaengert.pdf
Padayachee ST, Thomas N, Arnold AJ, Inusa B. Problems with implementing a standardised transcranial Doppler screening programme: impact of instrumentation variation on STOP classification. Pediatr Radiol. 2012;42(4):470‐474.
Mogayzel PJ, Dunitz J Jr, Marrow LC, Hazle LA. Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Qual Saf. 2014;23(1):i3‐i8.
Hulbert ML, Manwani D, Meier ER, et al. Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center. Pediatr Blood Cancer. 2023;70(1):e29961.
Greenwood S, Deane C, Rees OL, et al. The significance of inadequate transcranial Doppler studies in children with sickle cell disease. PLoS One. 2017;12(7):e0181681.
Inusa BPD, Sainati L, MacMahon C, et al. An educational study promoting the delivery of transcranial Doppler ultrasound screening in paediatric sickle cell disease: a European multi‐centre perspective. J Clin Med. 2019;9(1):44.
Mañú Pereira MDM, Colombatti R, Alvarez F, et al. Sickle cell disease landscape and challenges in the EU: the ERN‐EuroBloodNet perspective. Lancet Haematol. 2023;10(8):e687‐e694.
Schlenz AM, Phillips S, Mueller M, et al. Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE consortium. Pediatr Blood Cancer. 2020;67(4):e28172.
Phillips SM, Schlenz AM, Mueller M, Melvin CL, Adams RJ, Kanter J. Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium. Implement Sci Commun. 2021;2(1):87.
Reeves SL, Madden B, Freed GL, Dombkowski KJ. Transcranial Doppler screening among children and adolescents with sickle cell anemia. JAMA Pediatr. 2016;170(6):550‐556.
Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US Federal and Foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Netw Open. 2020;3(3):e201737.
Montanaro M, Colombatti R, Pugliese M, et al. Intellectual function evaluation of first generation immigrant children with sickle cell disease: the role of language and sociodemographic factors. Ital J Pediatr. 2013;39:36.
Luengo‐Fernandez R, Burns R, Leal J. Economic burden of non‐malignant blood disorders across Europe: a population‐based cost study. Lancet Haematol. 2016;3(8):e371‐e378.
Lee S, Vania DK, Bhor M, Revicki D, Abogunrin S, Sarri G. Patient‐reported outcomes and economic burden of adults with sickle cell disease in the United States: a systematic review. Int J Gen Med. 2020;13:361‐377.
Thielen FW, Houwing ME, Cnossen MH, et al. Cost of health care for paediatric patients with sickle cell disease: an analysis of resource use and costs in a European country. Pediatr Blood Cancer. 2020;67(9):e28588.
Ghafuri DL, Covert Greene B, Musa B, et al. Capacity building for primary stroke prevention teams in children living with sickle cell anemia in Africa. Pediatr Neurol. 2021;125:9‐15.
Brown LC, Hampton KC, Bloom EM, Lawson D, Cooper SH, Meier ER. No child left behind: building a comprehensive sickle cell disease care oasis in the Lake County, Indiana care desert. Pediatr Blood Cancer. 2022;69(8):e29619.
Haug CJ, Drazen JM. Artificial intelligence and machine learning in clinical medicine, 2023. N Engl J Med. 2023;388(13):1201‐1208.
Cooper A, Rodman A. AI and medical education—a 21st‐century pandora's box. N Engl J Med. 2023;389(5):385‐387.
International neurovascular training course on sickle cell disease. EuroBloodNet; 2023. Accessed December 20, 2023. https://eurobloodnet.eu/media/upload/arxius/Congresses/DEP‐International‐neurovascolar‐padova‐mar23.pdf
Piel FB, Rees DC, DeBaun MR, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633‐e686.
Kwiatkowski JL, Granger S, Brambilla DJ, et al. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol. 2006;134(3):333‐339.
Bernaudin F, Arnaud C, Kamdem A, et al. Incidence, kinetics, and risk factors for intra‐ and extracranial cerebral arteriopathies in a newborn sickle cell disease cohort early assessed by transcranial and cervical color Doppler ultrasound. Front Neurol. 2022;13:846596.